BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25113248)

  • 1. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
    Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting focal adhesion kinase signaling in tumor growth and metastasis.
    Schwock J; Dhani N; Hedley DW
    Expert Opin Ther Targets; 2010 Jan; 14(1):77-94. PubMed ID: 20001212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAK inhibitors in Cancer, a patent review.
    Lv PC; Jiang AQ; Zhang WM; Zhu HL
    Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
    Schultze A; Fiedler W
    Expert Opin Investig Drugs; 2010 Jun; 19(6):777-88. PubMed ID: 20465362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAK signaling in human cancer as a target for therapeutics.
    Lee BY; Timpson P; Horvath LG; Daly RJ
    Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal transduction by focal adhesion kinase in cancer.
    Zhao J; Guan JL
    Cancer Metastasis Rev; 2009 Jun; 28(1-2):35-49. PubMed ID: 19169797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal adhesion kinase as potential target for cancer therapy (Review).
    Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Wang ZG; Takaoka M
    Oncol Rep; 2009 Nov; 22(5):973-9. PubMed ID: 19787209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal adhesion kinase: a potential target in cancer therapy.
    van Nimwegen MJ; van de Water B
    Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal adhesion kinase as a cancer therapy target.
    Golubovskaya VM
    Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAK expression regulation and therapeutic potential.
    Li S; Hua ZC
    Adv Cancer Res; 2008; 101():45-61. PubMed ID: 19055942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
    Shi Q; Hjelmeland AB; Keir ST; Song L; Wickman S; Jackson D; Ohmori O; Bigner DD; Friedman HS; Rich JN
    Mol Carcinog; 2007 Jun; 46(6):488-96. PubMed ID: 17219439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles of focal adhesion kinase in cancer.
    Tai YL; Chen LC; Shen TL
    Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of methyl violet 2B as a novel blocker of focal adhesion kinase signaling pathway in cancer cells.
    Kim H; Kim ND; Lee J; Han G; Sim T
    Biochem Biophys Res Commun; 2013 Jul; 437(2):319-24. PubMed ID: 23817042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
    Chauhan A; Khan T
    Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
    Lu Y; Sun H
    J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
    Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
    Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials.
    Mohanty A; Pharaon RR; Nam A; Salgia S; Kulkarni P; Massarelli E
    Expert Opin Investig Drugs; 2020 Apr; 29(4):399-409. PubMed ID: 32178538
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
    Lv P; Chen K; Zhu HL
    Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.
    Wu X; Wang J; Liang Q; Tong R; Huang J; Yang X; Xu Y; Wang W; Sun M; Shi J
    Biomed Pharmacother; 2022 Jul; 151():113116. PubMed ID: 35598365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.